Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela Cohen

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
EMS Magazine|October 31, 2008
Your voice is neededPamela Cohen
Journal of the American Pharmacists Association : Japha|December 29, 2024
Increasing SGLT-2 inhibitor prescribing through an integrated case-finding algorithm-guided interdisciplinary interventionCindy Leslie A Roberson, Abby F Hoffman, Pamela Cohen, et al.
The American Journal of Managed Care|March 8, 2024
Improving glycemic control in diabetes through virtual interdisciplinary roundsAbby F Hoffman, Cindy Leslie Roberson, Pamela Cohen, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3Purva Bali, Prince George, Pamela Cohen, et al.
Blood|July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsMark Levis, Patrick Brown, B Douglas Smith, et al.
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
EMS Magazine|October 31, 2008
Your voice is neededPamela Cohen
Journal of the American Pharmacists Association : Japha|December 29, 2024
Increasing SGLT-2 inhibitor prescribing through an integrated case-finding algorithm-guided interdisciplinary interventionCindy Leslie A Roberson, Abby F Hoffman, Pamela Cohen, et al.
The American Journal of Managed Care|March 8, 2024
Improving glycemic control in diabetes through virtual interdisciplinary roundsAbby F Hoffman, Cindy Leslie Roberson, Pamela Cohen, et al.
Cancer Research|May 20, 2004
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3Prince George, Purva Bali, Pamela Cohen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3Purva Bali, Prince George, Pamela Cohen, et al.
Blood|July 22, 2006
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitorsMark Levis, Patrick Brown, B Douglas Smith, et al.
Blood|September 4, 2004
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone, Daniel J DeAngelo, Virginia Klimek, et al.
Pageof 1